Drug
Tarlatamab
Drug Profile
| Therapeutic Class | Immunotherapy |
| Drug Class | bispecific T-cell engagers |
| Group | BiTE |
| Mechanism of Action | Bispecific T-cell engager |
| Half-life | 11 d |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Theoretical immune synergy (RT reinvigorates T cells, ↑antigen/infiltration); no DNA-level sensitization (Lu and Deng, Journal of Clinical Investigation, 2026; Ababneh et al., Radiotherapy and Oncology, 2026). The relevant theoretical risk is amplified cytokine-release/neurological adverse events from immune activation rather than in-field radiation adverse events.
Data on this page refer exclusively to patients treated with
Tarlatamab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
BiTE group page.